CN1137691C - 基于天然雌激素的多相避孕制剂 - Google Patents

基于天然雌激素的多相避孕制剂 Download PDF

Info

Publication number
CN1137691C
CN1137691C CNB961233605A CN96123360A CN1137691C CN 1137691 C CN1137691 C CN 1137691C CN B961233605 A CNB961233605 A CN B961233605A CN 96123360 A CN96123360 A CN 96123360A CN 1137691 C CN1137691 C CN 1137691C
Authority
CN
China
Prior art keywords
daily dosage
natural
estrogen
phase
dosage units
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB961233605A
Other languages
English (en)
Chinese (zh)
Other versions
CN1159917A (zh
Inventor
M
M·迪根
S·弗力克
H·霍夫曼
C·穆尔
ض�
M·厄特尔
M·奥斯特塔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Bayer Intellectual Property GmbH
Original Assignee
Jenapharm GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7776074&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1137691(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jenapharm GmbH and Co KG filed Critical Jenapharm GmbH and Co KG
Publication of CN1159917A publication Critical patent/CN1159917A/zh
Application granted granted Critical
Publication of CN1137691C publication Critical patent/CN1137691C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Amplifiers (AREA)
  • Gyroscopes (AREA)
  • Permanent Magnet Type Synchronous Machine (AREA)
CNB961233605A 1995-10-28 1996-10-28 基于天然雌激素的多相避孕制剂 Expired - Lifetime CN1137691C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19540253.7 1995-10-28
DE19540253A DE19540253C2 (de) 1995-10-28 1995-10-28 Mehrphasenpräparat zur Kontrazeption auf der Basis natürlicher Estrogene

Publications (2)

Publication Number Publication Date
CN1159917A CN1159917A (zh) 1997-09-24
CN1137691C true CN1137691C (zh) 2004-02-11

Family

ID=7776074

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB961233605A Expired - Lifetime CN1137691C (zh) 1995-10-28 1996-10-28 基于天然雌激素的多相避孕制剂

Country Status (18)

Country Link
US (2) US6133251A (enExample)
EP (1) EP0770388B1 (enExample)
JP (1) JP3020880B2 (enExample)
CN (1) CN1137691C (enExample)
AT (1) ATE164312T1 (enExample)
CA (1) CA2188907C (enExample)
CZ (1) CZ290741B6 (enExample)
DE (3) DE19540253C2 (enExample)
DK (1) DK0770388T3 (enExample)
ES (1) ES2116804T3 (enExample)
FR (1) FR09C0018I2 (enExample)
HU (1) HU223753B1 (enExample)
LU (1) LU91643I2 (enExample)
NL (1) NL300381I2 (enExample)
PL (1) PL186339B1 (enExample)
RU (1) RU2113849C1 (enExample)
SI (1) SI0770388T1 (enExample)
SK (1) SK281709B6 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050032756A1 (en) * 1995-10-28 2005-02-10 Michael Dittgen Multistage preparation for contraception based on natural estrogens
FR2754179B1 (fr) 1996-10-08 1998-12-24 Theramex Nouvelle composition hormononale et son utilisation
WO2001030355A1 (fr) 1999-10-25 2001-05-03 Laboratoire Theramex Medicament contraceptif a base d'un progestatif et d'un estrogene et son mode de preparation
US6479535B1 (en) * 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
CA2267743C (en) 1999-03-30 2011-07-26 Robert F. Casper Low dose estrogen interrupted hormone replacement therapy
AU2005201151B2 (en) * 1999-03-30 2008-01-10 Jencap Research Ltd Low dose estrogen interrupted hormone replacement therapy
RS50262B2 (sr) * 1999-08-31 2018-10-31 Bayer Pharma AG Farmaceutska kombinacija etinilestradiola i drospirenona za primenu kao kontraceptivnog sredstva
US6787531B1 (en) 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
US7297688B2 (en) 2000-06-08 2007-11-20 Wyeth Starter kit for low dose oral contraceptives
NZ533242A (en) 2001-12-05 2007-11-30 Duramed Pharmaceuticals Inc Oral extended regime contraceptive package
TWI252111B (en) * 2001-12-14 2006-04-01 Solvay Pharm Gmbh Matrix film tablet with controlled release of a natural mixture of conjugated estrogens
TW200403065A (en) * 2002-05-30 2004-03-01 Akzo Nobel Nv New etonogestrel esters
US20040072814A1 (en) 2002-10-11 2004-04-15 Solvay Pharmaceuticals Gmbh Method for obtaining a natural mixture of conjugated equine estrogens depleted in non-conjugated lipophilic compounds
AR041121A1 (es) * 2002-10-11 2005-05-04 Solvay Pharm Gmbh Procedimiento para la obtencion de una mezcla natural de estrogenos conjugados
EP1535618A1 (en) * 2003-11-26 2005-06-01 Schering Aktiengesellschaft Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions
DE102004019743B4 (de) * 2004-04-20 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens
ATE546144T1 (de) * 2005-10-13 2012-03-15 Bayer Pharma AG Verwendung von estradiolvalerat in kombination mit dienogest zur oralen therapie der dysf unktionellen uterinen blutung in einheit mit einer oralen kontrazeption
EP1787649B1 (de) * 2005-10-13 2009-03-11 Bayer Schering Pharma Aktiengesellschaft Verwendung von Estradiolvalerat in Kombination mit Dienogest zur oralen Therapie der dysfunktionellen uterinen Blutung in Einheit mit einer oralen Kontrazeption
US8153616B2 (en) 2005-10-17 2012-04-10 Bayer Pharma Aktiengesellschaft Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
WO2007106264A2 (en) * 2006-03-02 2007-09-20 Warner Chilcott Company, Inc. Extended cycle multiphasic oral contraceptive method
EP1930010A1 (de) 2006-10-20 2008-06-11 Bayer Schering Pharma Aktiengesellschaft Verwendung von Estradiolvalerat oder 17ß-Estradiol in Kombination mit Dienogest zur oralen Therapie für den Erhalt und/oder die Steigerung der weiblichen Libido
RS62297B1 (sr) 2011-11-23 2021-09-30 Therapeuticsmd Inc Prirodne kombinovane hormonske supstitucione formulacije i terapije
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
JP2017516768A (ja) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然の併用ホルモン補充療法剤及び療法
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4292315A (en) * 1977-12-30 1981-09-29 Nichols Vorys Follicular phase estrogen or progestin with physiologic estrogen/progestin luteal phase replacement drug delivery system
US4390531A (en) * 1981-08-10 1983-06-28 Syntex Pharmaceuticals International Ltd. Method of contraception using peak progestogen dosage
US4921843A (en) * 1988-10-20 1990-05-01 Pasquale Samuel A Contraception system and method
IE62665B1 (en) * 1990-12-17 1995-02-22 Akzo Nv Contraceptive regimen
DE4104385C1 (enExample) * 1991-02-09 1992-08-13 Marika Dr.Med. 6509 Framersheim De Ehrlich
DE4224534A1 (de) * 1992-07-24 1994-01-27 Marika Dr Med Ehrlich Ovulationshemmendes Mittel zur hormonalen Kontrazeption
DE4308406C1 (de) * 1993-03-12 1994-06-16 Jenapharm Gmbh Kombinationspräparat zur Kontrazeption
DE4339934C2 (de) * 1993-05-07 1995-05-24 Klaus Dr Med Umbreit Ovulationshemmendes Mittel zur hormonalen Kontrazeption
NL9301562A (nl) * 1993-09-09 1995-04-03 Saturnus Ag Preparaat voor substitutietherapie.
DE4344462C2 (de) * 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
DE4429374C1 (de) * 1994-08-12 1996-02-01 Jenapharm Gmbh Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente

Also Published As

Publication number Publication date
SK281709B6 (sk) 2001-07-10
CA2188907C (en) 2001-02-27
DK0770388T3 (da) 1999-01-11
SI0770388T1 (en) 1998-08-31
HUP9602982A2 (en) 1997-05-28
HUP9602982A3 (en) 1997-10-28
DE122009000011I1 (de) 2009-05-20
PL316608A1 (en) 1997-05-12
DE19540253C2 (de) 1998-06-04
DE19540253A1 (de) 1997-04-30
CZ290741B6 (cs) 2002-10-16
NL300381I2 (nl) 2017-05-22
JP3020880B2 (ja) 2000-03-15
EP0770388B1 (de) 1998-03-25
US6133251A (en) 2000-10-17
CA2188907A1 (en) 1997-04-29
FR09C0018I1 (enExample) 2009-09-25
DE59600128D1 (de) 1998-04-30
RU2113849C1 (ru) 1998-06-27
EP0770388A1 (de) 1997-05-02
ATE164312T1 (de) 1998-04-15
ES2116804T3 (es) 1998-07-16
SK135296A3 (en) 1997-06-04
PL186339B1 (pl) 2003-12-31
US20020107229A1 (en) 2002-08-08
LU91643I2 (fr) 2010-03-29
CZ9603043A3 (cs) 2002-01-16
HU223753B1 (hu) 2005-01-28
NL300381I1 (nl) 2009-06-02
CN1159917A (zh) 1997-09-24
DE122009000011I2 (de) 2011-07-21
HU9602982D0 (en) 1996-12-30
FR09C0018I2 (fr) 2015-05-22
JPH09169649A (ja) 1997-06-30
US6884793B2 (en) 2005-04-26

Similar Documents

Publication Publication Date Title
CN1137691C (zh) 基于天然雌激素的多相避孕制剂
CN1108800C (zh) 用于激素避孕的药物混合制剂
CN1128613C (zh) 用于绝经前后妇女激素代替疗法中的孕甾醇拮抗剂与具有部分紧张作用的抗雌激素的结合体
RU2122854C1 (ru) Комбинированный препарат для контрацепции, фармацевтическая упаковка для контрацепции
CN1189101A (zh) 用于激素避孕的药物复合制剂、药盒和方法
CN1036834C (zh) 避孕药盒的制备方法
CN1905885A (zh) 包含雌激素和孕激素的延长应用组合
CN1186024C (zh) 单阶段避孕方法和含有黄体酮和雌激素组合物的避孕药盒
JPH04290830A (ja) 避妊薬処方物
CZ288062B6 (cs) Přípravek pro ženskou antikoncepci
KR19990076685A (ko) 게스타겐 및 에스트로겐의 배합을 포함하는 암컷 포유동물용 피임 방법 및 키트
CN1077430C (zh) 激素避孕法的药物复合制剂
CN1119999C (zh) 口服避孕药
CN1186023C (zh) 双相避孕方法及包含孕激素和雌激素组合物的药剂盒
CN1270521A (zh) 第一阶段包含孕激素/雌激素并且第二阶段包含孕激素的口服避孕制剂
US6642219B1 (en) Progestogen-antiprogestogen regimens
WO1999009993A1 (en) Combinations of endometrial sparing progestins and endometrial atrophizing progestins with estrogens, in oral contraception
WO2023037264A1 (en) Contraceptive regimen including reduced level of estrogen
CN101119732A (zh) 避孕药物制剂
CN1950092A (zh) 对延长的激素避孕方案中突破性出血的控制
HK1102771A (en) Management of breakthrough bleeding in extended hormonal contraceptive regimens
HK1097185A (en) Extended use combination comprising estrogens and progestins
CA2371635A1 (en) Use of antiprogestagens in combined therapy
HK1024420A (en) Hormonal composition consisting of an oestrogen compound and of a progestational compound
HK1186108A (en) Management of breakthrough bleeding in extended hormonal contraceptive regimens

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: SCHERING CORP.

Free format text: FORMER OWNER: JENAPHARM GMBH + CO. KG

Effective date: 20050812

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20050812

Address after: Berlin

Patentee after: SCHERING Corp.

Address before: Analytik Jena

Patentee before: Jenapharm GmbH & Co.KG

ASS Succession or assignment of patent right

Owner name: BAYER SCHERING PHARMA AG

Free format text: FORMER OWNER: SCHERING CORP.

Effective date: 20091204

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20091204

Address after: Berlin

Patentee after: BAYER SCHERING PHARMA AG

Address before: Berlin

Patentee before: SCHERING Corp.

ASS Succession or assignment of patent right

Owner name: BAYER INTELLECTUAL PROPERTY GMBH

Free format text: FORMER OWNER: BAYER PHARMACEUTICALS AG

Effective date: 20130322

C41 Transfer of patent application or patent right or utility model
C56 Change in the name or address of the patentee

Owner name: BAYER PHARMACEUTICALS AG

Free format text: FORMER NAME: BAYER SCHERING PHARMA AG

CP01 Change in the name or title of a patent holder

Address after: Berlin

Patentee after: BAYER PHARMA AG

Address before: Berlin

Patentee before: Bayer Schering Pharma AG

TR01 Transfer of patent right

Effective date of registration: 20130322

Address after: German Monheim

Patentee after: BAYER INTELLECTUAL PROPERTY GmbH

Address before: Berlin

Patentee before: BAYER PHARMA AG

CX01 Expiry of patent term

Granted publication date: 20040211

EXPY Termination of patent right or utility model